NorthWest Biotherapeutics Inc (NWBO)

[skitahoe]

Polska,

While I believe it should go dramatically higher on approval, what if you were right. $4 would be over a 5 banger from where we are today, what other stocks are you in that will give you a 5 banger between now and a year from now.

I believe we all think that NWBO ought to be at least $2 now, if it were, $4 would be a double, still not a bad return.

Think about it, with regulatory approval what person who's discovered having a brain cancer, not just GBM, isn't going to want to get treatment with DCVax-L if their tumor is operable, so the vaccine can be made. In the beginning I believe the demand may be hard to fill, but it will rapidly grow. It really won't be long before earning will be in the billions of dollars a year. Even if massive dilution took our OS to near 2 billion we could still have earnings equaling $1 or more a share by 2024, perhaps sooner. What's a fair P/E for a company who's earnings are growing by billions a year, I believe that 30 is fair, but it could actually go higher especially if by 2024 we have trial evidence that DCVax-Direct is showing benefits in a variety of cancers.

I believe we could do better than $30 by 2024, but who would complain about that sort of growth from where we are today. Certainly we may be bought out for less than that sooner, but if not, even if we were over $2 now, that would be a 15 banger by then, but from where we are now it's well over a 40 banger. How many other stocks do you know of with that sort of potential.

I'm certainly open to criticism on what I'm suggesting, if you cannot see my numbers, what do you think they should be. Do you believe that most people diagnosed with brain cancers won't want DCVax-L, or that insurance won't pay most costs of using it, so they'll decline. I believe most people want to live and all the evidence is telling me that DCVax-L combined with other therapeutics which currently would be off label for brain cancer, but available and probably covered by insurance, may approach 30 to 40% survival at 5 years. They don't work without DCVax-L, but with it they clearly are providing advantages in trials at UCLA.

Gary